Literature DB >> 6432698

Serum sensitivity of a Pseudomonas aeruginosa mucoid strain.

N L Schiller, M J Alazard, R S Borowski.   

Abstract

The susceptibility of Pseudomonas aeruginosa 144M (a mucoid strain isolated from the sputum of a cystic fibrosis patient) to the bactericidal activity of pooled fresh normal human serum (FHS) was examined. FHS at concentrations of greater than or equal to 2.5% was capable of killing greater than 95% of strain 144M. Strain 144M was killed by FHS in a dose-dependent manner. Although either immunoglobulin M (IgM) or IgG was bactericidal in the presence of complement, IgM was about 10 times as effective as IgG. However, optimal killing activity required both IgM and IgG and complement, activated by the classical pathway. A role for lysozyme in the killing of 144M was demonstrated only when low concentrations of FHS were used. In contrast to 144M, P. aeruginosa strains 144NM and 144M(SR) were totally resistant to FHS at all of the concentrations tested (up to 50%). Neither the FHS susceptibility of 144M nor the FHS resistance of 144NM or 144M(SR) was altered by choice of growth medium, growth phase, or temperature of growth. Results of absorption studies with whole organisms, isolated outer membrane preparations, or lipopolysaccharide (LPS) from each strain suggest that the antigen(s) which binds the bactericidal immunoglobulins is accessible on the surface of 144M but not on the surface of 144NM or 144M(SR), is insensitive to trypsin treatment, and is believed to be LPS. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the three LPS preparations demonstrated that 144M LPS contained primarily lipid-A-core polysaccharide components, whereas the LPS from 144NM and 144M(SR) were heterogeneous, with various degrees of O-side-chain substitution. These results suggest that at least one target for bactericidal antibody on the surface of 144M is contained in the rough LPS of this strain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432698      PMCID: PMC263361          DOI: 10.1128/iai.45.3.748-755.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Studies on the additive effect of polymyxin B and the bactericidal activity of human serum against Serratia marcescens.

Authors:  W H Traub; I Kleber
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

2.  Killing of an encapsulated strain of Escherichia coli by human serum.

Authors:  P W Taylor; H P Kroll
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

3.  Plasmid-mediated and temperature-regulated surface properties of Yersinia enterocolitica.

Authors:  R J Martinez
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

4.  The relationship between the O-antigenic lipopolysaccharides and serological specificity in strains of Pseudomonas aeruginosa of different O-serotypes.

Authors:  I R Chester; P M Meadow; T L Pitt
Journal:  J Gen Microbiol       Date:  1973-10

5.  Ultrastructural surface alterations of serratia marcescens after exposure to polymyxin B and/or fresh human serum.

Authors:  W H Traub; G Acker; I Kleber
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

6.  A complement-sensitive mutant of Pseudomonas aeruginosa.

Authors:  C Offredo-Hemmer; P Berche; M Véron
Journal:  Ann Microbiol (Paris)       Date:  1983 May-Jun

7.  Sensitivity of Pseudomonas aeruginosa to normal serum and to polymyxin.

Authors:  L H Muschel; L A Ahl; M W Fisher
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

8.  Serum-induced lysis of Pseudomonas aeruginosa.

Authors:  T Meshulam; H Verbrugh; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1982-02       Impact factor: 3.267

9.  Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis.

Authors:  J Lam; R Chan; K Lam; J W Costerton
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

10.  Development of an enzyme-linked immunosorbent assay for studying Pseudomonas aeruginosa cell surface antigens.

Authors:  R S Borowski; L M Stock; N L Schiller
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

View more
  18 in total

1.  Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing.

Authors:  S Merino; S Camprubí; S Albertí; V J Benedí; J M Tomás
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing.

Authors:  S Merino; X Rubires; A Aguilar; S Albertí; S Hernandez-Allés; V J Benedí; J M Tomas
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa.

Authors:  N L Schiller; K A Joiner
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

Review 5.  Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Authors:  Samuel M Moskowitz; Ronald L Gibson; Eric L Effmann
Journal:  Pediatr Radiol       Date:  2005-05-03

6.  Role of lipopolysaccharide and complement in susceptibility of Klebsiella pneumoniae to nonimmune serum.

Authors:  B Ciurana; J M Tomás
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

7.  Killing of Gram-negative bacteria with normal human serum and normal bovine serum: use of lysozyme and complement proteins in the death of Salmonella strains O48.

Authors:  G Bugla-Płoskońska; A Kiersnowski; B Futoma-Kołoch; W Doroszkiewicz
Journal:  Microb Ecol       Date:  2009-03-18       Impact factor: 4.552

Review 8.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 9.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

10.  Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway.

Authors:  S K Kochi; R C Johnson
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.